Role of homologous recombination in trabectedin-induced DNA damage.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Journal of Cancer

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ejca.2008.01.003PMID 18243687
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743

  2007cited by this paper
• Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair.

  2007cited by this paper
• Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript

  2007cited by this paper
• Dynamics of cell cycle phase perturbations by trabectedin (ET‐743) in nucleotide excision repair (NER)‐deficient and NER‐proficient cells, unravelled by a novel mathematical simulation approach

  2007cited by this paper
• Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

  2007cited by this paper
• Targeting DNA repair as a promising approach in cancer therapy.

  2007cited by this paper
• Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy

  2006cited by this paper
• DNA double-strand break repair: all's well that ends well.

  2006cited by this paper
• DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.

  2006cited by this paper
• DNA double-strand break repair: a relentless hunt uncovers new prey.

  2006cited by this paper
• Sub‐nuclear localization of Rad51 in response to DNA damage

  2006cited by this paper
• Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function.

  2006cited by this paper
• ET-743: a novel agent with activity in soft-tissue sarcomas

  2006cited by this paper
• Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.

  2006cited by this paper
• Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

  2005cited by this paper
• Differential and collaborative actions of Rad51 paralog proteins in cellular response to DNA damage

  2005cited by this paper
• DNA repair: the importance of phosphorylating histone H2AX.

  2005cited by this paper
• Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

  2005cited by this paper
• Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways.

  2005cited by this paper
• Histone H2A phosphorylation in DNA double‐strand break repair

  2005cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.

  2004cited by this paper
• The combination of yondelis and cisplatin is synergistic against human tumor xenografts.

  2003cited by this paper
• Unique features of the mode of action of ET-743.

  2002cited by this paper
• The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.

  2001cited by this paper
• Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair

  2001cited by this paper
• Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

  2001cited by this paper
• Unique pattern of ET‐743 activity in different cellular systems with defined deficiencies in DNA‐repair pathways

  2001cited by this paper
• DNA Repair Protein Rad55 Is a Terminal Substrate of the DNA Damage Checkpoints

  2000cited by this paper
• Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

  1999cited by this paper
• NMR-BASED MODEL OF AN ECTEINASCIDIN 743-DNA ADDUCT

  1997cited by this paper
• Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti‐cancer agents

  1996cited by this paper
• DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.

  1996cited by this paper
• Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line

  1995cited by this paper

• Trabectedin Induces Synthetic Lethality via the p53-Dependent Apoptotic Pathway in Ovarian Cancer Cells Without BRCA Mutations When Used in Combination with Niraparib

  2025cites this paper
• Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background

  2024cites this paper
• Unleashing precision: a review of targeted approaches in pleural mesothelioma.

  2024cites this paper
• Long-term efficacy of eribulin in patients with advanced myxoid liposarcoma resistant to trabectedin: A case report

  2024cites this paper
• Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial

  2024cites this paper
• Prognostic nutrition index as a predictive factor for overall survival in trabectedin-treated advanced soft tissue sarcoma.

  2024cites this paper
• From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

  2022cites this paper
• Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells

  2022cites this paper
• Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers

  2022cites this paper
• Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment

  2022cites this paper
• Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells

  2022cites this paper
• DNA repair and damage pathways in mesothelioma development and therapy

  2022cites this paper
• Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

  2022cites this paper
• DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination

  2022cites this paper
• Trabectedin

  2021cites this paper
• Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.

  2021cites this paper
• A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.

  2020cites this paper
• Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.

  2020cites this paper
• Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center

  2020cites this paper
• [A Case of Primary Ewing Sarcoma of the Kidney Treated with Multidisciplinary Approach].

  2020cites this paper
• Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts

  2020cites this paper
• Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines

  2019cites this paper
• Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

  2019cites this paper
• Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells

  2019cites this paper
• Platinum Resistance in Ovarian Cancer: Role of DNA Repair

  2019cites this paper
• Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia

  2018cites this paper
• Trabectedin in Ovarian Cancer: is it now a Standard of Care?

  2018cites this paper
• Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models1

  2017cites this paper
• Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality?

  2017cites this paper
• The efficacy of trabectedin in treating ovarian cancer

  2017cites this paper
• Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms

  2017cites this paper
• Oceans: Abode of Nutraceuticals, Pharmaceuticals, and Biotoxins

  2017cites this paper
• Trabectedin mechanism of action and platinum resistance: molecular rationale.

  2017cites this paper
• Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1‐acid glycoprotein

  2017cites this paper
• Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcription

  2017cites this paper
• 1. Targeting Enzymatic Pathways with Marine-Derived Clinical Agents

  2017cites this paper
• Mechanism of action of trabectedin in desmoplastic small round cell tumor cells

  2017cites this paper
• Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

  2016cites this paper
• Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.

  2016cites this paper
• Unique features of trabectedin mechanism of action

  2016cites this paper
• Trabectedin for the treatment of breast cancer

  2016cites this paper
• Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair

  2016cites this paper
• Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge

  2016cites this paper
• Trabectedin for the treatment of soft tissue sarcomas

  2016cites this paper
• The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer

  2016cites this paper
• Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma

  2016cites this paper
• Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.

  2015cites this paper
• Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

  2015cites this paper
• Therapeutic Agents Based on DNA Sequence Specific Binding.

  2015cites this paper
• Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents

  2015cites this paper
• Targeting the EWS–FLI1 transcription factor in Ewing sarcoma

  2015cites this paper
• Trabectedin in Soft Tissue Sarcomas

  2015cites this paper
• Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin

  2015cites this paper
• Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer

  2015influential citation
• O PAPEL DA TRABECTEDINA NOS SARCOMAS

  2015cites this paper
• Трабектедин - лиганд узкой бороздки ДНК

  2015cites this paper
• Trabectedin (ET-743) from Marine Tunicate for Cancer Treatment

  2015cites this paper
• The Pathogenesis of Ewing Sarcoma. Implications of Mesenchymal Stem Cells and New Therapeutic Strategies

  2015cites this paper
• From old alkylating agents to new minor groove binders.

  2014cites this paper
• Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

  2014cites this paper
• Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

  2014cites this paper
• Mode of action of trabectedin in myxoid liposarcomas

  2014cites this paper
• Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a review.

  2014influential citation
• Innovative Therapies in Ewing Sarcoma

  2014cites this paper
• A Comprehensive Safety Evaluation of Trabectedin and Drug–Drug Interactions of Trabectedin-Based Combinations

  2014cites this paper
• Resistance to minor groove binders.

  2014cites this paper
• Safety evaluation of trabectedin in treatment of soft-tissue sarcomas

  2013cites this paper
• Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

  2013cites this paper
• Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

  2013cites this paper
• Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.

  2013cites this paper
• P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.

  2013cites this paper
• Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)

  2013cites this paper
• Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors

  2013cites this paper
• Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response

  2013cites this paper
• Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo.

  2012cites this paper
• Characterization of a new trabectedin‐resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

  2012cites this paper
• A phase I trial and pharmacokinetic study of a 24‐hour infusion of trabectedin (Yondelis®, ET‐743) in children and adolescents with relapsed or refractory solid tumors

  2012cites this paper
• Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.

  2012cites this paper
• Management of Ovarian Cancer and Soft Tissue Sarcoma: Focus on Trabectedin

  2011cites this paper
• Activity of trabectidin in desmoplastic small round cell tumor

  2011cites this paper
• Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.

  2011cites this paper
• DNA Helix Destabilization by Alkylating Agents: From Covalent Bonding to DNA Repair

  2011influential citation
• Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.

  2011cites this paper
• A Journey Under the Sea: The Quest for Marine Anti-Cancer Alkaloids

  2011cites this paper
• XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

  2011cites this paper
• Acute Myeloid Leukemia Unlikely Related to Trabectedin Treatment

  2011cites this paper
• Trabectedin

  2010cites this paper
• Action A Review of Trabectedin ( ET-743 ) : A Unique Mechanism of Updated

  2010cites this paper
• PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity

  2010cites this paper
• Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors

  2010cites this paper
• Actionof Trabectedin (ET-743): A Unique Mechanism of

  2010cites this paper
• Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.

  2010cites this paper
• A Review of Trabectedin (ET-743): A Unique Mechanism of Action

  2010cites this paper
• Trabectedin therapy for sarcomas

  2010cites this paper
• Liposarcoma: Molecular Genetics and Therapeutics

  2010influential citation
• eview of Trabectedin ( ET-743 ) : A Unique Ther hanism of Action zio

  2010cites this paper
• Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

  2010cites this paper
• Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

  2009cites this paper
• Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

  2009cites this paper
• Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?

  2009cites this paper